We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KBR Set to Provide Delivery Support to Sellafield in U.K.
Read MoreHide Full Article
KBR, Inc. (KBR - Free Report) has received a £500-million contract from the U.K. Government's Nuclear Decommissioning Authority-owned Sellafield Ltd. to act as one of the delivery partners for the latter’s major construction projects and infrastructure program in the United Kingdom.
KBR will support safe and secure decommissioning of the Sellafield nuclear site. This framework contract, which has a total value of approximately £4.5 billion, has a duration of more than 20 years.
Per the contract, KBR will provide program and project management services, along with project-specific delivery plans for all major projects at Sellafield, including mobilization of resources, coordination of logistic requirements and interpretation of delivery strategies. Also, it will coordinate the development of an integrated management system, and procurement management, estimating, quantity surveying, risk management, document controls and commercial services.
Additionally, the company, as an integration partner, will conjugate with clients and three other Program and Project Partners to form an integrated delivery team. The team along with supply chain will improve capability, enhance project delivery, and support social value and local economic development. Also, the team will contribute to the U.K. industrial strategy and nuclear sector deal.
KBR has been supporting nuclear programs in the U.K. over the past few years. On Apr 26, 2019, the company received a support contract from the U.K. Ministry of Defence to provide communications network support and training services in the Middle East.
As of Mar 31, 2019, KBR recorded a backlog of $13.6 billion compared with $13.5 billion in the corresponding period of 2018, highlighting its underlying strength. Markedly, nearly 80% of the backlog represents work in Government Solutions. The company believes that the recent contract wins will ultimately help in margin expansion and considerably de-risking business.
Notably, shares of KBR have outperformed its industry so far this year. The stock has gained 49.5% compared with its industry’s collective growth of 19.6%. The solid performance is backed by the company’s impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing five quarters. First-quarter 2019 marked its 9th consecutive quarter of strong revenues, earnings and cash flow; impressive year-over-year backlog growth; and the successful integration of SGT and Aspire.
Going forward, KBR expects broad-based growth across all segments. Primary growth drivers include high-end and differentiated government business work, strong margin performance, and the technology and consulting business.
Other top-ranked stocks in the Zacks Construction sector include EMCOR Group, Inc. (EME - Free Report) , AECOM (ACM - Free Report) and Quanta Services, Inc. (PWR - Free Report) . While EMCOR sports a Zacks Rank #1, both AECOM and Quanta Services carry a Zacks Rank #2.
EMCOR and AECOM surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average being 14.5% and 6.2%, respectively.
Quanta Services’ earnings for the current year are likely to grow 28.8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
KBR Set to Provide Delivery Support to Sellafield in U.K.
KBR, Inc. (KBR - Free Report) has received a £500-million contract from the U.K. Government's Nuclear Decommissioning Authority-owned Sellafield Ltd. to act as one of the delivery partners for the latter’s major construction projects and infrastructure program in the United Kingdom.
.jpg)
KBR will support safe and secure decommissioning of the Sellafield nuclear site. This framework contract, which has a total value of approximately £4.5 billion, has a duration of more than 20 years.
Per the contract, KBR will provide program and project management services, along with project-specific delivery plans for all major projects at Sellafield, including mobilization of resources, coordination of logistic requirements and interpretation of delivery strategies. Also, it will coordinate the development of an integrated management system, and procurement management, estimating, quantity surveying, risk management, document controls and commercial services.
Additionally, the company, as an integration partner, will conjugate with clients and three other Program and Project Partners to form an integrated delivery team. The team along with supply chain will improve capability, enhance project delivery, and support social value and local economic development. Also, the team will contribute to the U.K. industrial strategy and nuclear sector deal.
KBR has been supporting nuclear programs in the U.K. over the past few years. On Apr 26, 2019, the company received a support contract from the U.K. Ministry of Defence to provide communications network support and training services in the Middle East.
As of Mar 31, 2019, KBR recorded a backlog of $13.6 billion compared with $13.5 billion in the corresponding period of 2018, highlighting its underlying strength. Markedly, nearly 80% of the backlog represents work in Government Solutions. The company believes that the recent contract wins will ultimately help in margin expansion and considerably de-risking business.
Notably, shares of KBR have outperformed its industry so far this year. The stock has gained 49.5% compared with its industry’s collective growth of 19.6%. The solid performance is backed by the company’s impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing five quarters. First-quarter 2019 marked its 9th consecutive quarter of strong revenues, earnings and cash flow; impressive year-over-year backlog growth; and the successful integration of SGT and Aspire.
Going forward, KBR expects broad-based growth across all segments. Primary growth drivers include high-end and differentiated government business work, strong margin performance, and the technology and consulting business.
Zacks Rank & Other Key Picks
Currently, KBR carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other top-ranked stocks in the Zacks Construction sector include EMCOR Group, Inc. (EME - Free Report) , AECOM (ACM - Free Report) and Quanta Services, Inc. (PWR - Free Report) . While EMCOR sports a Zacks Rank #1, both AECOM and Quanta Services carry a Zacks Rank #2.
EMCOR and AECOM surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average being 14.5% and 6.2%, respectively.
Quanta Services’ earnings for the current year are likely to grow 28.8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>